Skip to main content

Advertisement

SpringerLink
Log in

Transplantation for chemotherapy-induced cardiomyopathy—case series and review of current practice

  • Review Article
  • Published:
Indian Journal of Thoracic and Cardiovascular Surgery Aims and scope Submit manuscript

Abstract

Multimodality therapies have improved the survival after tumors like Ewing’s sarcoma and breast cancer. However, cardiotoxicity following chemotherapy remains an important concern. We report a case series of four patients who presented to our heart team with severe dilated cardiomyopathy along with biventricular involvement. Two of the patients were females and had breast cancer for which they were treated with trastuzumab and had developed chemotherapy induced cardiomyopathy (CCMP). The other two patients were males who had Ewing’s sarcoma who developed CCMP following treatment with doxorubicin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Oliveira GH, Qattan MY, Al-Kindi S, Park SJ. Advanced heart failure therapies for patients with chemotherapy-induced cardiomyopathy. Circ Heart Fail. 2014;7:1050–8.

  2. Oliveira GH, Hardaway BW, Kucheryavaya AY, Stehlik J, Edwards LB, Taylor DO. Characteristics and survival of patients with chemotherapy-induced cardiomyopathy undergoing heart transplantation. J Heart Lung Transplant. 2012;31:805–10.

    Article  Google Scholar 

  3. Ghosh N, Hilton J. Orthotopic heart transplantation and mechanical circulatory support in cancer survivors: challenges and outcomes. J Oncol. 2015; https://doi.org/10.1155/2015/232607.

  4. Shakir DK, Rasul KI. Chemotherapy induced cardiomyopathy: pathogenesis, monitoring and management. J Clin Med Res. 2009;1:8–12.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Piper SE, McDonagh TA. Chemotherapy-related cardiomyopathy. Eur Cardiol. 2015;10:19–24.

    Article  Google Scholar 

  6. Cardinale D, Colombo A, Cipolla CM. Prevention and treatment of cardiomyopathy and heart failure in patients receiving cancer chemotherapy. Curr Treat Options Cardiovasc Med. 2008;10:486–95.

    Article  Google Scholar 

  7. Longhi A, Ferrari S, Tamburini A, et al. Late effects of chemotherapy and radiotherapy in osteosarcoma and Ewing sarcoma patients: the Italian Sarcoma Group Experience (1983-2006). Cancer. 2012;118:5050–9.

  8. Bacci G, Longhi A, Fagioli F, Briccoli A, Versari M, Picci P. Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy. Eur J Cancer. 2005;41:2836–2845.

  9. Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation. 1996;93:841–2.

    Article  CAS  Google Scholar 

  10. Singh TP, Sleeper LA, Lipshultz S, et al. Association of left ventricular dilation at listing for heart transplant with postlisting and early posttransplant mortality in children with dilated cardiomyopathy. Circ Heart Fail. 2009;2:591–8.

  11. Jones RL, Ewer MS. The hallmark of doxorubicin induced cardiomyopathy is a HF syndrome arising from dilated cardiomyopathy (DCM). Expert Rev Anticancer Ther. 2006;6:1249–69.

    Article  CAS  Google Scholar 

  12. Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18:1639–42.

    Article  Google Scholar 

  13. Ryberg M, Nielsen D, Cortese G, Nielsen G, Skovsgaard T, Andersen PK. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst. 2008;100:1058–67.

    Article  CAS  Google Scholar 

  14. Wouters KA, Kremer LCM, Miller TL, Herman EH, Lipshultz SE. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol. 2005;131:561–78.

    Article  CAS  Google Scholar 

  15. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97:2869–79.

    Article  CAS  Google Scholar 

  16. Baselga J, Albanell J. Mechanism of action of anti-HER2 monoclonal antibodies. Ann Oncol. 2001;12:S35–41.

    Article  Google Scholar 

  17. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–92.

    Article  CAS  Google Scholar 

  18. Bennani-Baiti IM, Cooper A, Lawlor ER, et al. Intercohort gene expression co- analysis reveals chemokine receptors as prognostic indicators in Ewing’s sarcoma. Clin Cancer Res.2010;16: 3769-78.

  19. Yeh ETH, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53:2231–47.

    Article  CAS  Google Scholar 

  20. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf. 2000;22:263–302.

    Article  CAS  Google Scholar 

  21. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005;23:4265–74.

    Article  CAS  Google Scholar 

  22. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487–98.

    Article  CAS  Google Scholar 

  23. Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc. 2008;83:679–86.

    Article  Google Scholar 

  24. Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008;26:5204–12.

    Article  Google Scholar 

  25. Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol. 2014;63:2751–68.

    Article  Google Scholar 

  26. Curigliano G, Cardinale D, Suter T, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23:vii155–66.

    Article  Google Scholar 

  27. Herman EH, Zhang J, Lipshultz SE, et al. Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol. 1999;17:2237–43.

    Article  CAS  Google Scholar 

  28. Morandi P, Ruffini PA, Benvenuto GM, la Vecchia L, Mezzena G, Raimondi R. Serum cardiac troponin I levels and ECG/Echo monitoring in breast cancer patients undergoing high-dose (7 g/m(2)) cyclophosphamide. Bone Marrow Transplant. 2001;28:277–82.

    Article  CAS  Google Scholar 

  29. Specchia G, Buquicchio C, Pansini N, et al. Monitoring of cardiac function on the basis of serum troponin I levels in patients with acute leukemia treated with anthracyclines. J Lab Clin Med. 2005;145:212–20.

    Article  CAS  Google Scholar 

  30. Purkayastha K, Seth R, Seth S, Lyon AR. Cancer therapy-induced cardiotoxicity: review and algorithmic approach toward evaluation. J Pract Cardiovasc Sci. 2017;3:82–93.

    Article  Google Scholar 

  31. Wieczorek SJ, Wu AHB, Christenson R, et al. A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: A multicenter evaluation. Am Heart J. 2002;144:834–9.

  32. Lipshultz SE, Miller TL, Scully RE, et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol. 2012;30:1042–9.

    Article  CAS  Google Scholar 

  33. Sawaya H, Sebag IA, Plana JC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging. 2012;5:596–603.

    Article  Google Scholar 

  34. Bosch X, Rovira M, Sitges M, et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol. 2013;61:2355–62.

    Article  CAS  Google Scholar 

  35. Mancini D, Lietz K. Selection of cardiac transplantation candidates in 2010. Circulation. 2010;122:173–83.

    Article  Google Scholar 

  36. Cavigelli-Brunner A, Schweiger M, Knirsch W, et al. VAD as bridge to recovery in anthracycline-induced cardiomyopathy and HHV6 myocarditis. Pediatrics. 2014;134:e894–9.

    Article  Google Scholar 

  37. Appel JM, Sander K, Hansen PB, Møller JE, Krarup-Hansen A, Gustafsson F. Left ventricular assist device as bridge to recovery for anthracycline-induced terminal heart failure. Congest Heart Fail. 2012;18:291–4.

    Article  CAS  Google Scholar 

  38. Jurczak W, Szmit S, Sobociński M, et al. Premature cardiovascular mortality in lymphoma patients treated with (R)-CHOP regimen—a national multicenter study. Int J Cardiol. 2013;168:5212–7.

    Article  Google Scholar 

  39. Florescu M, Cinteza M, Vinereanu D. Chemotherapy-induced Cardiotoxicity. Maedica (Buchar). 2013;8:59–67.

    Google Scholar 

  40. Bloom MW, Hamo CE, Cardinale D, et al. Cancer therapy-related cardiac dysfunction and heart failure: part 1: definitions, pathophysiology, risk factors, and imaging. Circ Heart Fail. 2016;9:e002661.

    Article  Google Scholar 

  41. Awadalla M, Hassan MZO, Alvi RM, Neilan TG. Advanced imaging modalities to detect cardiotoxicity. Curr Probl Cancer. 2018;42:386–96.

    Article  Google Scholar 

  42. Cook GJR. PET and PET/CT imaging of skeletal metastases. Cancer Imaging. 2010;10:1–8.

    Article  Google Scholar 

  43. Potena L,Pellegrini C, Grigioni F, et al. Optimizing the safety profile of everolimus by delayed initiation in De Novo heart transplant recipients:Results of the prospective randomized study EVERHEART. Transplantation. 2018;102:493–501.

Download references

Funding

No funding was required for this article.

Author information

Authors and Affiliations

  1. Cardiac Sciences, Institute of Heart and Lung Transplant and Mechanical Circulatory Support, MGM Healthcare, Chennai, Tamil Nadu, India

    Komarakshi Rajagopalan Balakrishnan

  2. Cardiac Anaesthesia & Critical Care, MGM Healthcare, Chennai, Tamil Nadu, India

    Kemundel Genny Suresh Rao

  3. MGM Healthcare, Chennai, Tamil Nadu, India

    Ganapathy Subramaniam

  4. Department of Cardiothoracic and Vascular Surgery, SMS Medical College & attached hospitals, Jaipur, Rajasthan, India

    Dhruva Sharma

Authors
  1. Komarakshi Rajagopalan Balakrishnan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kemundel Genny Suresh Rao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ganapathy Subramaniam
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dhruva Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dhruva Sharma.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Consent of the patient

Written informed consent was obtained from all the patients for publication of this case series and accompanying images.

Ethical approval

Ethical approval was not required as this is case series and review.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Balakrishnan, K.R., Rao, K.G.S., Subramaniam, G. et al. Transplantation for chemotherapy-induced cardiomyopathy—case series and review of current practice. Indian J Thorac Cardiovasc Surg 36 (Suppl 2), 287–293 (2020). https://doi.org/10.1007/s12055-020-01018-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12055-020-01018-8

Keywords

Search

Navigation